| 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre … L Gianni, T Pienkowski, YH Im, LM Tseng, MC Liu, A Lluch, ... The lancet oncology 17 (6), 791-800, 2016 | 890 | 2016 |
| Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study E Alba, L Calvo, J Albanell, JR De la Haba, AA Lanza, JI Chacon, ... Annals of oncology 23 (12), 3069-3074, 2012 | 236 | 2012 |
| First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or … M Rimawi, JM Ferrero, J de la Haba-Rodriguez, C Poole, S De Placido, ... Journal of Clinical Oncology 36 (28), 2826-2835, 2018 | 207 | 2018 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 198 | 2022 |
| Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy A Santonja, A Sánchez-Muñoz, A Lluch, MR Chica-Parrado, J Albanell, ... Oncotarget 9 (41), 26406, 2018 | 177 | 2018 |
| Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study M Martín, S Loibl, G von Minckwitz, S Morales, N Martinez, A Guerrero, ... Journal of Clinical Oncology 33 (9), 1045-1052, 2015 | 166 | 2015 |
| CoCl2, a Mimic of Hypoxia, Induces Formation of Polyploid Giant Cells with Stem Characteristics in Colon Cancer LM Lopez-Sánchez, C Jimenez, A Valverde, V Hernandez, J Penarando, ... PloS one 9 (6), e99143, 2014 | 145 | 2014 |
| Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial JM Pérez-García, M Vaz Batista, P Cortez, M Ruiz-Borrego, JM Cejalvo, ... Neuro-oncology 25 (1), 157-166, 2023 | 137 | 2023 |
| Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial G Bianchini, L Pusztai, T Pienkowski, YH Im, GV Bianchi, LM Tseng, ... Annals of Oncology 26 (12), 2429-2436, 2015 | 135 | 2015 |
| Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01) A Lluch, CH Barrios, L Torrecillas, M Ruiz-Borrego, J Bines, J Segalla, ... Journal of clinical oncology 38 (3), 203-213, 2020 | 121 | 2020 |
| Nitric oxide and cancer: the emerging role of S-nitrosylation E Aranda, C Lopez-Pedrera, J R De La Haba-Rodriguez, ... Current molecular medicine 12 (1), 50-67, 2012 | 118 | 2012 |
| Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive … C Pico, M Martin, C Jara, A Barnadas, A Pelegri, A Balil, C Camps, A Frau, ... Annals of Oncology 15 (1), 79-87, 2004 | 116 | 2004 |
| Patterns in the size structure of the phytoplankton community in the deep fluorescence maximum of the Alboran Sea (southwestern Mediterranean) J Rodrıguez, JM Blanco, F Jiménez-Gómez, F Echevarrıa, J Gil, ... Deep Sea Research Part I: Oceanographic Research Papers 45 (10), 1577-1593, 1998 | 108 | 1998 |
| Anxiety, depression, and asthma control: changes after standardized treatment J Sastre, A Crespo, A Fernandez-Sanchez, M Rial, V Plaza, FC González, ... The Journal of Allergy and Clinical Immunology: In Practice 6 (6), 1953-1959, 2018 | 105 | 2018 |
| Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant … M Martin, C Zielinski, M Ruiz-Borrego, E Carrasco, N Turner, EM Ciruelos, ... Annals of oncology 32 (4), 488-499, 2021 | 99 | 2021 |
| Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial E Alba, J Albanell, J de la Haba, A Barnadas, L Calvo, P Sánchez-Rovira, ... British journal of cancer 110 (5), 1139-1147, 2014 | 90 | 2014 |
| Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor–positive, ERBB2-negative advanced breast cancer: a randomized … A Llombart-Cussac, JM Pérez-García, M Bellet, F Dalenc, M Gil-Gil, ... JAMA oncology 7 (12), 1791-1799, 2021 | 72 | 2021 |
| In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and … L Artigas, M Coma, P Matos-Filipe, J Aguirre-Plans, J Farrés, R Valls, ... PLoS One 15 (10), e0240149, 2020 | 70 | 2020 |
| Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy … P Gibbs, V Heinemann, NK Sharma, J Taieb, J Ricke, M Peeters, ... Clinical colorectal cancer 17 (4), e617-e629, 2018 | 70 | 2018 |
| Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer … M Martín, A Ruiz Simon, M Ruiz Borrego, N Ribelles, ... Journal of Clinical Oncology 33 (32), 3788-3795, 2015 | 70 | 2015 |
Zarate RUniversidad de Navarra在 unav.es 的电子邮件经过验证
